Head to head
CagriSema against Tirzepatide
The two highest weight loss figures in late stage obesity development, from different mechanisms: amylin plus GLP-1 against GIP plus GLP-1. One is approved and one is filed, and no trial has randomised people between them.
Column A
CagriSemaCagriSema (cagrilintide + semaglutide)
A fixed combination of the amylin analogue cagrilintide and semaglutide that produced about 23% weight loss in Phase 3 and has been filed for FDA approval.
Column B
TirzepatideTirzepatide (dual GIP/GLP-1 receptor agonist)
A first-in-class dual GIP and GLP-1 receptor agonist with superior weight loss and glycemic control versus GLP-1 mono-agonists.
Side by side, on the facts we can check
| Attribute | CagriSema | Tirzepatide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | Investigational; NDA submitted to the FDA in December 2025 (REDEFINE 1 and 2); decision expected 2026 | FDA-approved (Mounjaro for T2D and, from August 2026, to reduce major cardiovascular events in T2D; Zepbound for weight management and sleep apnea) |
| Half-life | ~7 days (weekly dosing) | ~5 days |
| Molecular weight | Mixture; cagrilintide 4,409 Da plus semaglutide 4,113.6 Da | 4,813.5 Da |
| Mechanism | Simultaneously agonizes amylin receptors (satiety) and the GLP-1 receptor (appetite, insulin, gastric emptying) for additive weight loss. | Simultaneously activates GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion, reducing glucagon, delaying gastric emptying, and reducing appetite. The GIP component is thought to add complementary metabolic effects. |
| Human studies cited | 3 | 4 |
| Legal status, US | Investigational, not approved | FDA-approved, prescription only |
Frequently asked questions
What is the difference between CagriSema and Tirzepatide?
CagriSema: A fixed combination of the amylin analogue cagrilintide and semaglutide that produced about 23% weight loss in Phase 3 and has been filed for FDA approval. Tirzepatide: A first-in-class dual GIP and GLP-1 receptor agonist with superior weight loss and glycemic control versus GLP-1 mono-agonists.
Which has stronger research evidence, CagriSema or Tirzepatide?
This database does not grade compounds. It counts what was run in people: 3 of the 3 studies cited on the CagriSema profile were human work, against 4 of 4 for Tirzepatide. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are CagriSema and Tirzepatide FDA-approved?
CagriSema: Investigational; NDA submitted to the FDA in December 2025 (REDEFINE 1 and 2); decision expected 2026. Tirzepatide: FDA-approved (Mounjaro for T2D and, from August 2026, to reduce major cardiovascular events in T2D; Zepbound for weight management and sleep apnea).
Related posts
Blog articles that cover CagriSema or Tirzepatide, newest first.
- Dispatch / Sep 12, 2026 / 8 minDispatch 001: Five Retatrutide Phase 3 Trials Have Finished And None Has Posted Results
- Metabolic / Sep 8, 2026 / 8 minTesofensine Is Not a Peptide: What It Is, the Trials, and the Heart-Rate Issue
- Metabolic / Sep 8, 2026 / 10 minOral GLP-1s in 2026: Wegovy Pill vs Foundayo (Orforglipron) vs Rybelsus, and What Is Coming
- Metabolic / Sep 8, 2026 / 9 minMariTide (Maridebart Cafraglutide): The Once-Monthly GLP-1 Agonist and GIP Blocker, Explained
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.